Wedbush analyst Robert Driscoll weighed in on Arbutus Biopharma (NASDAQ: ABUS) after Alnylam (NASDAQ: ALNY) reported positive data from its ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Hot Comments Momentum Movers Trader Talk

Alnylam Pharmaceuticals (ALNY) PT Raised to $123 at Credit SuisseSeptember 21, 2017 6:26 AM Alnylam Pharmaceuticals (ALNY) PT Raised to $125 at Needham & CompanySeptember 20, 2017 3:20 PM Alnylam Pharmaceuticals (ALNY) PT Raised to $83 at StifelSeptember 20, 2017 1:41 PM Alnylam Pharmaceuticals (ALNY) PT Raised to $117 at Cowen; 'Best-Case Scenario'September 20, 2017 12:36 PM Arbutus Biopharma (ABUS) and Alnylam Pharmaceuticals, Inc. (ALNY) Reports Positive Phase 3 Results for LNP-Enabled Patisiran ProgramSeptember 20, 2017 12:25 PM Alnylam Pharmaceuticals (ALNY) PT Raised to $116 at Piper JaffraySeptember 20, 2017 11:39 AM Alnylam Pharma (ALNY) Adds to Gains; Shares up 40%September 20, 2017 10:23 AM Arbutus Biopharma (ABUS) Gains Sharply Following Alnylam Trial SuccessSeptember 20, 2017 10:12 AM Pre-Open Stock Movers 09/20: (ALNY) (KPTI) (GEMP) Higher; (BBBY) (IONS) (GIS) Lower (more...)September 20, 2017 9:29 AM